Liver cancer patients: do pre-transplant drugs improve outcomes?
NCT ID NCT07418138
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked back at data from 484 liver cancer patients who had a liver transplant to see if taking certain cancer drugs (tyrosine kinase inhibitors) before the transplant helped them live longer or kept the cancer from coming back. The researchers checked survival rates, cancer recurrence, and liver function after surgery. The goal was to find out what factors affect patient outcomes after a liver transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital Xian Jiaotong University
Xi'an, Shaanxi, 710061, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lifesaving leukemia drug harm Men's sexual health?
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- A new Anti-Rejection strategy may spare kidney function after liver transplant
- Can a cell test free liver transplant patients from lifelong drugs?
- AI-Powered surveillance may outsmart liver cancer recurrence